Baidu
map

Neurosurgery:骨形态发生蛋白(BMP)可能增加良性肿瘤风险

2013-09-10 佚名 生物谷

发表在九月Neurosurgery杂志上的一项研究报告称:用骨形态发生蛋白(BMP)进行脊柱融合术的患者似乎患良性肿瘤的风险增加,但患癌症的风险不增加。【原文下载】 美国杜克大学医学中心Nandan博士和他的同事分析了脊柱融合手术中接受BMP的近4,700名患者的癌症和良性肿瘤风险。骨形态发生蛋白是一种生长因子,可以促进新骨形成。 它是FDA批准的用于一种特定类

发表在九月Neurosurgery杂志上的一项研究报告称:用骨形态发生蛋白(BMP)进行脊柱融合术的患者似乎患良性肿瘤的风险增加,但患癌症的风险不增加。【原文下载】

美国杜克大学医学中心Nandan博士和他的同事分析了脊柱融合手术中接受BMP的近4,700名患者的癌症和良性肿瘤风险。骨形态发生蛋白是一种生长因子,可以促进新骨形成。

它是FDA批准的用于一种特定类型的脊柱融合术,但已成为其他融合程序中广泛使用的“标签”。与以前的小型研究相反,与相匹配的无BMP脊柱融合术的患者相比,患者接受BMP,全身性或恶性癌的风险没有增加。

然而,调整后其他因素发现 BMP脊柱融合术患者良性肿瘤的相关​​风险较高,高出约30%。虽然绝对风险小,但接受BMP患者有较高风险的神经系统肿瘤,尤其是位于脊髓和大脑(脑膜)组织中的良性肿瘤。研究人员怀疑:这些软组织肿瘤的增加可能与脊柱周围的“大局部剂量”的BMP 相关。

这个大型的、独立的倾向性配对的研究结果表明,腰椎融合手术中使用BMP与较高的良性肿瘤风险显著相关,但BMP不会增加恶性肿瘤风险。

原文下载

Lad SP, Bagley JH, Karikari IO, Babu R, Ugiliweneza B, Kong M, Isaacs RE, Bagley CA, Gottfried ON, Patil CG, Boakye M.Cancer after spinal fusion: the role of bone morphogenetic protein.Neurosurgery. 2013 Sep;73(3):440-9. doi: 10.1227

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1877655, encodeId=818e18e7655da, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jun 06 11:08:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821603, encodeId=befe182160388, content=<a href='/topic/show?id=ebbe1016584f' target=_blank style='color:#2F92EE;'>#骨形态发生蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101658, encryptionId=ebbe1016584f, topicName=骨形态发生蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Tue May 27 19:08:00 CST 2014, time=2014-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633995, encodeId=0e931633995e3, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Tue Apr 22 10:08:00 CST 2014, time=2014-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026012, encodeId=202d20260128b, content=<a href='/topic/show?id=c3048314322' target=_blank style='color:#2F92EE;'>#肿瘤风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83143, encryptionId=c3048314322, topicName=肿瘤风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sat Feb 22 19:08:00 CST 2014, time=2014-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021468, encodeId=a17c202146875, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Feb 01 08:08:00 CST 2014, time=2014-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352666, encodeId=ee1a13526668f, content=<a href='/topic/show?id=1a318666656' target=_blank style='color:#2F92EE;'>#良性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86666, encryptionId=1a318666656, topicName=良性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Sep 12 02:08:00 CST 2013, time=2013-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363911, encodeId=628513639117f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Sep 12 02:08:00 CST 2013, time=2013-09-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1877655, encodeId=818e18e7655da, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jun 06 11:08:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821603, encodeId=befe182160388, content=<a href='/topic/show?id=ebbe1016584f' target=_blank style='color:#2F92EE;'>#骨形态发生蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101658, encryptionId=ebbe1016584f, topicName=骨形态发生蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Tue May 27 19:08:00 CST 2014, time=2014-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633995, encodeId=0e931633995e3, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Tue Apr 22 10:08:00 CST 2014, time=2014-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026012, encodeId=202d20260128b, content=<a href='/topic/show?id=c3048314322' target=_blank style='color:#2F92EE;'>#肿瘤风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83143, encryptionId=c3048314322, topicName=肿瘤风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sat Feb 22 19:08:00 CST 2014, time=2014-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021468, encodeId=a17c202146875, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Feb 01 08:08:00 CST 2014, time=2014-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352666, encodeId=ee1a13526668f, content=<a href='/topic/show?id=1a318666656' target=_blank style='color:#2F92EE;'>#良性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86666, encryptionId=1a318666656, topicName=良性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Sep 12 02:08:00 CST 2013, time=2013-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363911, encodeId=628513639117f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Sep 12 02:08:00 CST 2013, time=2013-09-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1877655, encodeId=818e18e7655da, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jun 06 11:08:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821603, encodeId=befe182160388, content=<a href='/topic/show?id=ebbe1016584f' target=_blank style='color:#2F92EE;'>#骨形态发生蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101658, encryptionId=ebbe1016584f, topicName=骨形态发生蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Tue May 27 19:08:00 CST 2014, time=2014-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633995, encodeId=0e931633995e3, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Tue Apr 22 10:08:00 CST 2014, time=2014-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026012, encodeId=202d20260128b, content=<a href='/topic/show?id=c3048314322' target=_blank style='color:#2F92EE;'>#肿瘤风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83143, encryptionId=c3048314322, topicName=肿瘤风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sat Feb 22 19:08:00 CST 2014, time=2014-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021468, encodeId=a17c202146875, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Feb 01 08:08:00 CST 2014, time=2014-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352666, encodeId=ee1a13526668f, content=<a href='/topic/show?id=1a318666656' target=_blank style='color:#2F92EE;'>#良性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86666, encryptionId=1a318666656, topicName=良性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Sep 12 02:08:00 CST 2013, time=2013-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363911, encodeId=628513639117f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Sep 12 02:08:00 CST 2013, time=2013-09-12, status=1, ipAttribution=)]
    2014-04-22 HNYYM
  4. [GetPortalCommentsPageByObjectIdResponse(id=1877655, encodeId=818e18e7655da, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jun 06 11:08:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821603, encodeId=befe182160388, content=<a href='/topic/show?id=ebbe1016584f' target=_blank style='color:#2F92EE;'>#骨形态发生蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101658, encryptionId=ebbe1016584f, topicName=骨形态发生蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Tue May 27 19:08:00 CST 2014, time=2014-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633995, encodeId=0e931633995e3, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Tue Apr 22 10:08:00 CST 2014, time=2014-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026012, encodeId=202d20260128b, content=<a href='/topic/show?id=c3048314322' target=_blank style='color:#2F92EE;'>#肿瘤风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83143, encryptionId=c3048314322, topicName=肿瘤风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sat Feb 22 19:08:00 CST 2014, time=2014-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021468, encodeId=a17c202146875, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Feb 01 08:08:00 CST 2014, time=2014-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352666, encodeId=ee1a13526668f, content=<a href='/topic/show?id=1a318666656' target=_blank style='color:#2F92EE;'>#良性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86666, encryptionId=1a318666656, topicName=良性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Sep 12 02:08:00 CST 2013, time=2013-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363911, encodeId=628513639117f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Sep 12 02:08:00 CST 2013, time=2013-09-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1877655, encodeId=818e18e7655da, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jun 06 11:08:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821603, encodeId=befe182160388, content=<a href='/topic/show?id=ebbe1016584f' target=_blank style='color:#2F92EE;'>#骨形态发生蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101658, encryptionId=ebbe1016584f, topicName=骨形态发生蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Tue May 27 19:08:00 CST 2014, time=2014-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633995, encodeId=0e931633995e3, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Tue Apr 22 10:08:00 CST 2014, time=2014-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026012, encodeId=202d20260128b, content=<a href='/topic/show?id=c3048314322' target=_blank style='color:#2F92EE;'>#肿瘤风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83143, encryptionId=c3048314322, topicName=肿瘤风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sat Feb 22 19:08:00 CST 2014, time=2014-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021468, encodeId=a17c202146875, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Feb 01 08:08:00 CST 2014, time=2014-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352666, encodeId=ee1a13526668f, content=<a href='/topic/show?id=1a318666656' target=_blank style='color:#2F92EE;'>#良性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86666, encryptionId=1a318666656, topicName=良性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Sep 12 02:08:00 CST 2013, time=2013-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363911, encodeId=628513639117f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Sep 12 02:08:00 CST 2013, time=2013-09-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1877655, encodeId=818e18e7655da, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jun 06 11:08:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821603, encodeId=befe182160388, content=<a href='/topic/show?id=ebbe1016584f' target=_blank style='color:#2F92EE;'>#骨形态发生蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101658, encryptionId=ebbe1016584f, topicName=骨形态发生蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Tue May 27 19:08:00 CST 2014, time=2014-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633995, encodeId=0e931633995e3, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Tue Apr 22 10:08:00 CST 2014, time=2014-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026012, encodeId=202d20260128b, content=<a href='/topic/show?id=c3048314322' target=_blank style='color:#2F92EE;'>#肿瘤风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83143, encryptionId=c3048314322, topicName=肿瘤风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sat Feb 22 19:08:00 CST 2014, time=2014-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021468, encodeId=a17c202146875, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Feb 01 08:08:00 CST 2014, time=2014-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352666, encodeId=ee1a13526668f, content=<a href='/topic/show?id=1a318666656' target=_blank style='color:#2F92EE;'>#良性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86666, encryptionId=1a318666656, topicName=良性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Sep 12 02:08:00 CST 2013, time=2013-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363911, encodeId=628513639117f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Sep 12 02:08:00 CST 2013, time=2013-09-12, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1877655, encodeId=818e18e7655da, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Jun 06 11:08:00 CST 2014, time=2014-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1821603, encodeId=befe182160388, content=<a href='/topic/show?id=ebbe1016584f' target=_blank style='color:#2F92EE;'>#骨形态发生蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101658, encryptionId=ebbe1016584f, topicName=骨形态发生蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Tue May 27 19:08:00 CST 2014, time=2014-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633995, encodeId=0e931633995e3, content=<a href='/topic/show?id=596635e549' target=_blank style='color:#2F92EE;'>#BMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3575, encryptionId=596635e549, topicName=BMP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d95322064897, createdName=HNYYM, createdTime=Tue Apr 22 10:08:00 CST 2014, time=2014-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026012, encodeId=202d20260128b, content=<a href='/topic/show?id=c3048314322' target=_blank style='color:#2F92EE;'>#肿瘤风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83143, encryptionId=c3048314322, topicName=肿瘤风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sat Feb 22 19:08:00 CST 2014, time=2014-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021468, encodeId=a17c202146875, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Sat Feb 01 08:08:00 CST 2014, time=2014-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352666, encodeId=ee1a13526668f, content=<a href='/topic/show?id=1a318666656' target=_blank style='color:#2F92EE;'>#良性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86666, encryptionId=1a318666656, topicName=良性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Sep 12 02:08:00 CST 2013, time=2013-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363911, encodeId=628513639117f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Sep 12 02:08:00 CST 2013, time=2013-09-12, status=1, ipAttribution=)]
    2013-09-12 lsndxfj

相关资讯

JBJS:单节段腰椎后路融合BMP并不比自体髂骨更有优势

自体髂骨移植植骨融合(ICBG)一直是脊柱融合术的金标准,但仍有接近2.8-39%不等的融合失败率。近十年,随着具有骨诱导活性的人工骨蛋白类rhBMP-2的开发,自体髂骨移植进行脊柱间植骨融合的地位受到了挑战。目前已有较多关于rhBMP-2应用效果的文献发表,多个多中心临床研究表明,rhBMP-2和ICBG在临床预后方面具有较多优势:手术时间,术中失血,住院周期,再手术率,恢复工作时间等均有所下降

Baidu
map
Baidu
map
Baidu
map